局灶治疗后监测——一项综合综述
本文对前列腺癌局灶治疗后的随访策略进行叙述性综述,指出目前尚无标准化循证随访方案,专家中心主要依赖自身经验或机构方案。综述汇总了肿瘤学与功能学结局及并发症的随访方式,包括定期PSA、多参数MRI和前列腺穿刺活检,并指出仍需研究评估不同随访策略的影响与理想时机以制定标准化方案。
要点
- 局灶治疗后肿瘤学成功通常定义为治疗区内活检证实无临床显著前列腺癌。
- 局灶治疗后首次MRI应在6-12个月进行,以避开消融相关伪影并避免失败时的诊断延迟。
- 12个月方案内前列腺穿刺活检(含靶向与系统活检)通常被认为是排除肿瘤持续或复发的首选方法。
核心结论
- 局灶治疗后的随访是多方面过程,涉及临床、影像学和组织学评估。
- 需要开展评估不同随访策略影响与理想时机的研究,以制定局灶治疗后的标准化方案。
研究设计与样本
- 叙述性文献综述,旨在探讨前列腺癌局灶治疗的不同随访方案,关注消融后肿瘤学与功能学结局及并发症。
主要发现
- 局灶治疗后肿瘤学成功通常定义为治疗区内活检证实无临床显著前列腺癌。
- 未治疗区域出现的新发前列腺癌通常反映患者选择不准确,应作为原发性前列腺癌治疗。
- 随访期间肿瘤学结局应通过定期PSA、多参数MRI和前列腺穿刺活检评估。
- PSA衍生物和新型生物标志物的使用仍存争议,因此不推荐。
- 局灶治疗后首次MRI应在6-12个月进行,以避免消融相关伪影并避免局灶治疗失败时的诊断延迟。
关键数值与推荐
- 12个月方案内前列腺穿刺活检,包括靶向和系统活检,通常被认为是排除肿瘤持续或复发的首选活检方法。
- 后续多参数MRI和活检应根据临床情况采取风险适应方法。
- 功能学结局应在第一年内使用经验证的问卷定期评估,此期间通常恢复至新的基线。
- 并发症虽不常见,但应严格监测,主要在第一个月内。
临床怎么用
- 随访期间应使用定期PSA、多参数MRI和前列腺穿刺活检评估肿瘤学结局。
- 局灶治疗后首次MRI应在6-12个月进行。
- 12个月方案内前列腺穿刺活检(含靶向与系统活检)通常被认为是排除肿瘤持续或复发的首选方法。
- 后续多参数MRI和活检应根据临床情况采取风险适应方法。
- 功能学结局应在第一年内使用经验证问卷定期评估,并发症主要在第一个月内严格监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: to date, no standardized, evidence-based follow-up schemes exist for the monitoring of patients who underwent focal therapy (FT) and expert centers rely mainly on their own experience and/or institutional protocols. We aimed to perform a comprehensive review of the most advantageous follow-up strategies and their rationale after FT for prostate cancer (PCa). METHODS: a narrative review of the literature was conducted to investigate different follow-up protocols of FT for PCa. Outcomes of interest were post-ablation oncological and functional outcomes and complications. RESULTS: Oncological success after FT was generally defined as the biopsy-confirmed absence of clinically significant PCa in the treated zone. De novo PCa in the untreated area usually reflects an inaccurate patient selection and should be treated as primary PCa. During follow-up, oncological outcomes should be evaluated with periodic PSA, multiparametric MRI and prostate biopsy. The use of PSA derivatives and new biomarkers is still controversial and therefore not recommended. The first MRI after FT should be performed between 6-12 months to avoid ablation-related artifacts and diagnostic delay in case of FT failure. Other imaging modalities, such as PSMA PET/CT scan, are promising but still need to be validated in the post-FT setting. A 12-month "for-protocol" prostate biopsy, including targeted and systematic biopsy, was generally considered the preferred biopsy method to rule out tumor persistence/recurrence. Subsequent mpMRIs and biopsies should follow a risk-adapted approach depending on the clinical scenario. Functional outcomes should be periodically assessed using validated questionnaires within the first year, when typically recover to a new baseline. Complications, despite uncommon, should be strictly monitored mainly in the first month. CONCLUSIONS: FT follow-up is a multifaceted process involving clinical, radiological, and histological assessment. Studies evaluating the impact of different follow-up strategies and ideal timings are needed to produce standardized protocols following FT.
引用
- Marra G, Marquis A, Suberville M, et al. Surveillance after Focal Therapy - a Comprehensive Review. Prostate Cancer Prostatic Dis. 2024. PMID: 39367182. doi:10.1038/s41391-024-00905-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。